Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04878094 · ClinicalTrials.gov registry record · Phase 3
A Study of Intra-operative Imaging in Women With Ovarian Cancer
A Phase 3 study of Ovarian Cancer and Ovarian Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 310
- Enrollment target
- 9
- Study locations
NCT04878094 is a Phase 3 study of Ovarian Cancer and Ovarian Carcinoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 310 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (57% lower). The trial reports 9 study locations across 4 states.
The verdict
NCT04878094, a Phase 3 study of Ovarian Cancer and Ovarian Carcinoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 310 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to find out whether using the PINPOINT imaging system intra-operatively can reduce the risk of anastomotic leaks and other complications after surgery for ovarian cancer, compared with standard intra-operative assessments alone. The PINPOINT endoscopic fluorescence imaging system uses a special camera and a fluorescent (glowing) dye that can evaluate the blood flow of the bowel in real-time. If there is an area that appears concerning, the surgeon can correct the problem during the procedure.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Endoscopy
- DIAGNOSTIC_TEST Intravenous Indocyanine Green/ICG injection
- DIAGNOSTIC_TEST PINPOINT endoscopic fluorescence imaging system
Study Locations (9)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Pennsylvania
- Jefferson Abington Hospital - Willow Grove
Texas
- Houston Methodist Cancer Center (Data Collection Only) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2026-05-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04878094
The ClinicalTrials.gov registry entry for NCT04878094 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (57% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Endoscopy is the first listed.
NCT04878094 reports 9 study locations spanning 4 distinct geographic areas - top geographies include New York, New Jersey, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04878094 about?
NCT04878094 is a clinical study titled "A Study of Intra-operative Imaging in Women With Ovarian Cancer". The purpose of this study is to find out whether using the PINPOINT imaging system intra-operatively can reduce the risk of anastomotic leaks and other complications after surgery for ovarian cancer, compared with standard intra-operative assessments alone. The PINPOINT endoscopic fluorescence imagi...
What is the current status of trial NCT04878094?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 310 participants. The study started on 2021-05-03. Estimated completion is 2026-05-03.
What conditions does trial NCT04878094 study?
This clinical trial studies the following conditions: Ovarian Cancer, Ovarian Carcinoma.
What interventions are being tested in trial NCT04878094?
The interventions under investigation include: Endoscopy (DIAGNOSTIC_TEST), Intravenous Indocyanine Green/ICG injection (DIAGNOSTIC_TEST), PINPOINT endoscopic fluorescence imaging system (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04878094?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04878094 being conducted?
This trial has 9 study locations across New Jersey, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.